Alessia Lodi, Ph.D.
Affiliations: | 2006 | Ohio State University, Columbus, Columbus, OH |
Area:
Food Science and Technology AgricultureGoogle:
"Alessia Lodi"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Yael Vodovotz | grad student | 2006 | Ohio State | |
| (Physico-chemical and molecular characterization of soy bread containing almond.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Stanford SM, Nguyen TP, Chang J, et al. (2024) Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy. Science Advances. 10: eadg7887 |
| Friedman CA, Saha A, Lavender Hackman G, et al. (2024) Novel two-tiered screening approach identifies synergistic combinations of natural compounds for prostate cancer prevention and treatment. Molecular Carcinogenesis |
| Konopleva M, DiNardo C, Bhagat T, et al. (2023) Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Research Square |
| Yap TA, Daver N, Mahendra M, et al. (2023) Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nature Medicine |
| Hua X, Li Y, Pentaparthi SR, et al. (2022) Landscape of microRNA regulatory network architecture and functional rerouting in cancer. Cancer Research |
| Lodi A, Pandey R, Chiou J, et al. (2022) Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide. Frontiers in Oncology. 12: 900082 |
| Baran N, Lodi A, Dhungana Y, et al. (2022) Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nature Communications. 13: 2801 |
| Lu X, Hackman GL, Saha A, et al. (2022) Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry. Iscience. 25: 104221 |
| Zhang Q, Riley-Gillis B, Han L, et al. (2022) Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy. 7: 110 |
| Zhang Q, Riley-Gillis B, Han L, et al. (2022) Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy. 7: 51 |